Consensus statements on the clinical understanding and use of bupropion in Hong Kong.

Autor: Lee WK; Department of Psychiatry, Kwai Chung Hospital, Hong Kong, China., Au Yeung KL; Private Practice, Hong Kong, China., Lam HB; Department of Psychiatry, Shatin Hospital, Hong Kong, China., Wong CK; Department of Psychiatry, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China., Wong TC; Private Practice, Hong Kong, China., Fu CK; Private Practice, Education, Prevention and Publication Subcommittee, The Mental Health Association of Hong Kong, Hong Kong, China., Sham SK; Private Practice, Hong Kong, China., Au MK; Private Practice, Hong Kong, China., Lam TC; Private Practice, The University of Hong Kong, Hong Kong, China., Ki-Yan Mak D; Private Practice, The Mental Health Association of Hong Kong, Hong Kong, China.
Jazyk: angličtina
Zdroj: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2021 Mar; Vol. 27 Suppl 1, pp. 20-24.
DOI: 10.1111/cns.13376
Abstrakt: Objectives: To develop a local consensus to guide medical practitioners and psychiatrists on the use of bupropion in different psychiatric conditions in Hong Kong.
Methods: By utilizing the modified Delphi technique, a group of 10 local physicians with extensive experience in the management of major depressive disorder (MDD) developed and voted (using an anonymous, electronic voting system) on the practicality of recommendation of a set of consensus statements on the clinical use and understanding of bupropion in Hong Kong.
Results: There was a very high degree of agreement among the panelists on the 11 finalized consensus statements.
Conclusions: The present consensus statements are developed as general recommendations for medical practitioners and psychiatrists to be practically referred to in clinical settings.
(© 2021 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje